Public comment period · §3
Draft monograph: Hexarelin — disposition
The disposition of every submission and the amendments that resulted.
§3Disposition and amendments
§3.1Disposition table
Table 1. Every submission with its disposition. Each row links to the submission in full.
| Reference | Respondent | Point raised | Disposition |
|---|---|---|---|
| DRAFT-HEXARELIN-MO/005 | Sigrún Vercingetorix | The population to which the headline estimate applies is not stated with the estimate | Accepted |
| DRAFT-HEXARELIN-MO/006 | Dr Odalys Thorsby-Nakamura industry | Two factual descriptions of the sponsor's programme are inaccurate | Accepted |
| DRAFT-HEXARELIN-MO/003 | Dr Lorcan Uttridge | Point estimates are given without an interval | Accepted in part |
| DRAFT-HEXARELIN-MO/004 | Dr Jacinta Grünbaum-Sowande | The analytical section is longer than the clinical assessment it accompanies | Accepted in part |
| DRAFT-HEXARELIN-MO/001 | Dr Oisín Rautavaara | A purity figure from a certificate is quoted as though it were a content figure | Accepted |
| DRAFT-HEXARELIN-MO/002 | Dr Gaspard Wintringham | Storage and reconstitution guidance is given without stating what it rests on | Accepted in part |
| DRAFT-HEXARELIN-MO/007 | Dr Ursina Ellsworth-Vance | The recorded evidence gaps omit outcomes a reader would consider material | Accepted in part |
| 7 submissions in total. | |||
§3.2Summary by disposition
Table 2. Counts by disposition, with the meaning of each.
| Disposition | Count | Meaning |
|---|---|---|
| Accepted | 3 | The submission is accepted and the draft is amended as proposed. The amendment is recorded in the amendment log of the document it changed and is traceable to the numbered submission. |
| Accepted in part | 4 | Part of the submission is accepted and part is not. The secretariat response states which part is which and on what ground the remainder was declined. |
| Noted, no amendment | 0 | The submission raises a point the Institute accepts but that does not require a change to the draft, most often because the draft already states it elsewhere. The location is given in the response. |
| Not accepted | 0 | The submission is not accepted. The secretariat response gives the reason. A submission that is not accepted remains published in full; the Institute does not remove a submission because it disagrees with it. |
§3.3Resulting amendments
- The population to which the headline estimate applies is not stated with the estimate — arising from DRAFT-HEXARELIN-MO/005. Every headline estimate now carries a one-line statement of the population in which it was observed, and the full eligibility criteria are reported in the included-studies table rather than only in the source.
- Two factual descriptions of the sponsor's programme are inaccurate — arising from DRAFT-HEXARELIN-MO/006. The trial status now reads as completed at a pre-specified interim analysis, with the analysis identified, and the dose is stated in the unit used in the approved labelling. The submission is identified as an industry submission on its face in accordance with…
- Point estimates are given without an interval — arising from DRAFT-HEXARELIN-MO/003. Every estimate now carries its interval where the source reported one, and where it did not, the estimate is annotated as reported without an interval rather than left to appear as a precise figure.
- The analytical section is longer than the clinical assessment it accompanies — arising from DRAFT-HEXARELIN-MO/004. The analytical section is reduced to compound-specific content and cross-references the relevant standards for the general procedure, which shortens it substantially without removing what is not available elsewhere.
- A purity figure from a certificate is quoted as though it were a content figure — arising from DRAFT-HEXARELIN-MO/001. Purity and content are now reported in separate rows with separate definitions, and the monograph states that a purity figure sets no bound on content and that a content figure requires a determination against a standard of assigned content.
- Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-HEXARELIN-MO/002. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.
- The recorded evidence gaps omit outcomes a reader would consider material — arising from DRAFT-HEXARELIN-MO/007. The evidence-gap section is now derived from the anchor and decision-relevant outcomes for the indication, and any such outcome measured by no contributing trial is recorded as not measured rather than omitted.
References cited on this page
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.
Compound Evidence Institute · CEI-CP-055/3 · https://compoundevidence.com/comment-periods/draft-hexarelin-monograph/disposition/ · retrieved 30 July 2026